混合认知行为疗法对乳腺癌、前列腺癌和结直肠癌幸存者高复发恐惧的疗效:SWORD研究——一项随机对照试验
SWORD随机对照试验纳入88例乳腺癌、前列腺癌或结直肠癌治愈性治疗后6个月至5年、癌症担忧量表评分≥14的高复发恐惧幸存者,按1:1随机接受混合认知行为疗法(bCBT,45例)或常规照护(CAU,43例)。bCBT组复发恐惧严重程度较CAU组显著降低(均值差-3.48,95%CI -4.69至-2.28,P<.001),效应量d=0.76;bCBT组临床显著改善率29%(13/45) vs CAU组0%(0/43),P<.001。
要点
- bCBT组复发恐惧严重程度较CAU组显著降低,均值差-3.48(95%CI -4.69至-2.28,P<.001),效应量d=0.76。
- bCBT组临床显著改善率为29%(13/45),CAU组为0%(0/43),P<.001。
- bCBT组自评改善率为71%(30/42),CAU组为32%(12/38),P<.001。
核心结论
- bCBT对癌症幸存者复发恐惧严重程度具有统计学和临床显著效果,是一种有前景的新治疗方法。
研究设计与样本
- 随机对照试验纳入88例乳腺癌、前列腺癌或结直肠癌治愈性治疗后6个月至5年、癌症担忧量表评分≥14的高复发恐惧幸存者。
- 参与者按1:1随机分配(按癌症类型分层)接受bCBT(45例)或常规照护(CAU,43例)。
- bCBT包括五次面对面和三次在线会话,在基线(T0)和3个月后(T1)完成问卷,采用意向性分析。
主要发现
- bCBT组复发恐惧严重程度较CAU组显著降低(均值差-3.48,95%CI -4.69至-2.28,P<.001),效应量d=0.76。
- bCBT组临床显著改善率为29%(13/45),CAU组为0%(0/43),P<.001。
- bCBT组自评改善率为71%(30/42),CAU组为32%(12/38),P<.001。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Fear of cancer recurrence (FCR) is a common problem experienced by cancer survivors. Approximately one third of survivors report high FCR. This study aimed to evaluate whether blended cognitive behavior therapy (bCBT) can reduce the severity of FCR in cancer survivors curatively treated for breast, prostate, or colorectal cancer. Patients and Methods This randomized controlled trial included 88 cancer survivors with high FCR (Cancer Worry Scale score ≥ 14) from 6 months to 5 years after cancer treatment. Participants were randomly allocated (ratio 1:1, stratified by cancer type) to receive bCBT, including five face-to face and three online sessions (n = 45) or care as usual (CAU; n = 43). Participants completed questionnaires at baseline (T0) and 3 months later (T1). The intervention group completed bCBT between T0 and T1. The primary outcome was FCR severity assessed with the Cancer Worry Scale. Secondary outcomes included other distress-related measures. Statistical (one-way between-group analyses of covariance) and clinical effects (clinically significant improvement) were analyzed by intention to treat. Results Participants who received bCBT reported significantly less FCR than those who received CAU (mean difference, -3.48; 95% CI, -4.69 to -2.28; P < .001) with a moderate-to-large effect size ( d = 0.76). Clinically significant improvement in FCR was significantly higher in the bCBT group than in the CAU group (13 [29%] of 45 compared with 0 [0%] of 43; P < .001); self-rated improvement was also higher in the bCBT group (30 [71%] of 42 compared with 12 [32%] of 38 in the CAU group; P < .001). Conclusion bCBT has a statistically and clinically significant effect on the severity of FCR in cancer survivors and is a promising new treatment approach.
引用
- van de Wal M, Thewes B, Gielissen M, et al. Efficacy of Blended Cognitive Behavior Therapy for High Fear of Recurrence in Breast, Prostate, and Colorectal Cancer Survivors: The SWORD Study, a Randomized Controlled Trial. J Clin Oncol. 2017. PMID: 28471726. doi:10.1200/JCO.2016.70.5301
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。